About the Authors

Steven G. Deeks

Steven.Deeks@ucsf.edu

Affiliation Department of Medicine, University of California, San Francisco, San Francisco, California, United States of America

Sharon R. Lewin

Affiliations Peter Doherty Institute of Infection and Immunity, University of Melbourne, and Royal Melbourne Hospital, Melbourne, Australia, Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia

Linda-Gail Bekker

Affiliation Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa

Competing Interests

I have read the journal’s policy and the authors of this manuscript have the following competing interests: SD is an advisor to InnaVirVax, Bionor Pharma and Bryologix and receives grant support from Gilead, Merck and ViiV. SL’s institution has received funding for investigator-initiated industry-sponsored studies from Merck, Gilead, Viiv Healthcare and Tetralogic and has also acted on the advisory board for and as consultancy to Callimune, Tetralogic, and InnaVirVax. LGB is employed by the Desmond Tutu HIV Centre, UCT and the Desmond Tutu HIV Foundation. She has received honoraria for technical inputs from Jansen and Merck in the last 5 years and her organisation has benefited from grants from Gilead, Merck and ViiV. SD, SL, and LGB served as guest editors on PLOS Medicine’s Special Issue on Advances in HIV Prevention, Treatment and Cure.